Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 3/2021

Open Access 01-09-2021 | Public Health | Original Research

Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based on Real-World Data

Authors: Gustavo dos Santos Fernandes, Daniel Campos, Andre Ballalai, Rodrigo Palhares, Mario R. A. da Silva, Daniel M. F. Palhares, Ben-Hur F. Neto, Fabio M. do R. Barros, Roberto de A. Gil, Aline Chagas, Flair José Carrilho

Published in: Journal of Gastrointestinal Cancer | Issue 3/2021

Login to get access

Abstract

Purpose

Describe sociodemographic and clinical characteristics of patients with hepatocellular carcinoma (HCC) and establish their history in the Brazilian public health system.

Methods

Retrospective observational study was conducted using the database from the Department of Informatics of the Unified Health System (DataSUS). Patients with at least one claim of HCC between July/2011 and June/2016 were included. A record linkage methodology was performed to obtain longitudinal data across different databases. Demographic and clinical data were evaluated, including the time elapsed between diagnosis of HCC risk-factors and the cancer development. Data was analyzed using descriptive statistics.

Results

A total of 28,822 HCC cases were identified between July/2011 and June/2016. Mean age was 59.7 years (SD = 14.7), and most patients were men (55.9%). The highest relative number of HCC cases was detected in the south of Brazil (> 20 cases/100,000 inhabitants). About 86.5% of the patients had diagnosis of HCC without previous liver diseases. Only 8% had diagnosis of chronic viral hepatitis and 3.5% cirrhosis. About 76% were diagnosed at an advanced stage, and only 11% of the patients had early stage HCC. Approximately 58% of patients with previous underlying liver diseases were diagnosed at early stages, compared with only 24% of patients without prior record of underlying diseases.

Conclusion

The diagnosis of HCC in the Brazilian public health is usually made in patients with no previous diagnosis of liver disease and in advanced stages, when no curative treatment is available and survival rates are low. Public health policies are key for the screening and monitoring liver disease and, consequently, HCC.
Literature
1.
go back to reference Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24(1):1–17.CrossRef Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24(1):1–17.CrossRef
3.
go back to reference Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25(2):74–85.CrossRef Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25(2):74–85.CrossRef
4.
go back to reference Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.CrossRef Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.CrossRef
5.
go back to reference Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127(5 Suppl 1):S56–61.CrossRef Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127(5 Suppl 1):S56–61.CrossRef
6.
go back to reference Shariff MI, Cox IJ, Gomaa AI, et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3(4):353–67.CrossRef Shariff MI, Cox IJ, Gomaa AI, et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3(4):353–67.CrossRef
7.
go back to reference Pinero F, Poniachik J, Ridruejo E, et al. Hepatocellular carcinoma in Latin America: diagnosis and treatment challenges. World J Gastroenterol. 2018;24(37):4224–9.CrossRef Pinero F, Poniachik J, Ridruejo E, et al. Hepatocellular carcinoma in Latin America: diagnosis and treatment challenges. World J Gastroenterol. 2018;24(37):4224–9.CrossRef
8.
go back to reference Carrilho FJ, Paranaguá-Vezozzo DC, Chagas AL, et al (2019) Epidemiology of liver cancer in Latin America: current and future trends. Semin Liv Dis Carrilho FJ, Paranaguá-Vezozzo DC, Chagas AL, et al (2019) Epidemiology of liver cancer in Latin America: current and future trends. Semin Liv Dis
9.
go back to reference Kikuchi L, Chagas AL, Alencar RSSM, et al. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Antivir Ther. 2013;18:445–9.CrossRef Kikuchi L, Chagas AL, Alencar RSSM, et al. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Antivir Ther. 2013;18:445–9.CrossRef
10.
go back to reference Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef
11.
go back to reference Zhang G, Li R, Deng Y, Zhao L. Conditional survival of patients with hepatocellular carcinoma: results from the Surveillance, Epidemiology, and End Results registry. Expert Rev Gastroenterol Hepatol. 2018 May;12(5):515–23.CrossRef Zhang G, Li R, Deng Y, Zhao L. Conditional survival of patients with hepatocellular carcinoma: results from the Surveillance, Epidemiology, and End Results registry. Expert Rev Gastroenterol Hepatol. 2018 May;12(5):515–23.CrossRef
12.
go back to reference Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol. 2016;22(41):9069–95.CrossRef Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol. 2016;22(41):9069–95.CrossRef
13.
go back to reference Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.CrossRef Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.CrossRef
14.
go back to reference Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34(2):153–9.CrossRef Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34(2):153–9.CrossRef
15.
go back to reference Paranagua-Vezozzo DC, Ono SK, Alvarado-Mora MV, et al. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort. Ann Hepatol. 2014;13(4):386–93.CrossRef Paranagua-Vezozzo DC, Ono SK, Alvarado-Mora MV, et al. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort. Ann Hepatol. 2014;13(4):386–93.CrossRef
16.
go back to reference Osório FMF, Lauar GM, Lima AS, et al. Epidemiological aspects of hepatocellular carcinoma in a referral center of Minas Gerais, Brazil. Arq Gastroenterol. 2013;50:97–100.CrossRef Osório FMF, Lauar GM, Lima AS, et al. Epidemiological aspects of hepatocellular carcinoma in a referral center of Minas Gerais, Brazil. Arq Gastroenterol. 2013;50:97–100.CrossRef
17.
go back to reference Almeida-Carvalho SR, Gomes-Ferraz ML, Loureiro-Matos CA, et al. Practical considerations of real life of hepatocellular carcinoma in a tertiary center of Brazil. Ann Hepatol. 2017;16(2):255–62.CrossRef Almeida-Carvalho SR, Gomes-Ferraz ML, Loureiro-Matos CA, et al. Practical considerations of real life of hepatocellular carcinoma in a tertiary center of Brazil. Ann Hepatol. 2017;16(2):255–62.CrossRef
18.
go back to reference Goncalves CS, Pereira FE, Gayotto LC. Hepatocellular carcinoma in Brazil: report of a national survey (Florianopolis, SC, 1995). Rev Inst Med Trop Sao Paulo. 1997;39(3):165–70.CrossRef Goncalves CS, Pereira FE, Gayotto LC. Hepatocellular carcinoma in Brazil: report of a national survey (Florianopolis, SC, 1995). Rev Inst Med Trop Sao Paulo. 1997;39(3):165–70.CrossRef
19.
go back to reference Castelo A, Pessôa MG, Barreto TCBB, et al. Estimativas de custo da hepatite crônica B no sistema único de saúde Brasileiro em 2005. Rev Assoc Méd Bras. 2007;53:486–91.CrossRef Castelo A, Pessôa MG, Barreto TCBB, et al. Estimativas de custo da hepatite crônica B no sistema único de saúde Brasileiro em 2005. Rev Assoc Méd Bras. 2007;53:486–91.CrossRef
20.
go back to reference Signorelli IV, Gonçalves PL, Gonçalves LL, et al. Socioeconomic disparities in access to a hepatocellular carcinoma screening program in Brazil. Clinics. 2016;71:361–4.CrossRef Signorelli IV, Gonçalves PL, Gonçalves LL, et al. Socioeconomic disparities in access to a hepatocellular carcinoma screening program in Brazil. Clinics. 2016;71:361–4.CrossRef
21.
go back to reference Kikuchi L, Chagas AL, Alencar R, et al. Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage. Clinics (Sao Paulo). 2017;72(8):454–60.CrossRef Kikuchi L, Chagas AL, Alencar R, et al. Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage. Clinics (Sao Paulo). 2017;72(8):454–60.CrossRef
22.
go back to reference Longo L, de Freitas LBR, Santos D, et al. Sorafenib for advanced hepatocellular carcinoma: a real-life experience. Dig Dis. 2018;36(5):377–84.CrossRef Longo L, de Freitas LBR, Santos D, et al. Sorafenib for advanced hepatocellular carcinoma: a real-life experience. Dig Dis. 2018;36(5):377–84.CrossRef
23.
go back to reference European Association for. The Study of The Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRef European Association for. The Study of The Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRef
24.
go back to reference Mendes EV. As redes de atenção à saúde. Ciênc Saúde Coletiva. 2010;15:2297–305.CrossRef Mendes EV. As redes de atenção à saúde. Ciênc Saúde Coletiva. 2010;15:2297–305.CrossRef
Metadata
Title
Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based on Real-World Data
Authors
Gustavo dos Santos Fernandes
Daniel Campos
Andre Ballalai
Rodrigo Palhares
Mario R. A. da Silva
Daniel M. F. Palhares
Ben-Hur F. Neto
Fabio M. do R. Barros
Roberto de A. Gil
Aline Chagas
Flair José Carrilho
Publication date
01-09-2021
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 3/2021
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-020-00508-7

Other articles of this Issue 3/2021

Journal of Gastrointestinal Cancer 3/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.